JPWO2020135335A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020135335A5 JPWO2020135335A5 JP2021536788A JP2021536788A JPWO2020135335A5 JP WO2020135335 A5 JPWO2020135335 A5 JP WO2020135335A5 JP 2021536788 A JP2021536788 A JP 2021536788A JP 2021536788 A JP2021536788 A JP 2021536788A JP WO2020135335 A5 JPWO2020135335 A5 JP WO2020135335A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- binding protein
- antigen binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 60
- 102000025417 antigen binding proteins Human genes 0.000 claims description 55
- 108091000829 antigen binding proteins Proteins 0.000 claims description 55
- 230000035693 Fab Effects 0.000 claims description 40
- 239000000427 antigen Substances 0.000 claims description 32
- 102000038129 antigens Human genes 0.000 claims description 32
- 108091007172 antigens Proteins 0.000 claims description 32
- 229920001184 polypeptide Polymers 0.000 claims description 26
- 201000011510 cancer Diseases 0.000 claims description 8
- 102100005826 CD19 Human genes 0.000 claims description 6
- 101700087100 CD19 Proteins 0.000 claims description 6
- 201000006934 chronic myeloid leukemia Diseases 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 claims description 5
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 claims description 5
- 235000001014 amino acid Nutrition 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 210000004027 cells Anatomy 0.000 claims description 5
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims description 4
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 claims description 4
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims description 4
- 108091007229 NSP3 Papain-like protease domain Proteins 0.000 claims description 4
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 claims description 4
- 125000000539 amino acid group Chemical group 0.000 claims description 4
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 4
- 201000003793 myelodysplastic syndrome Diseases 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 239000004475 Arginine Chemical group 0.000 claims description 2
- 208000009899 Burkitt Lymphoma Diseases 0.000 claims description 2
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-serine Chemical group OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 claims description 2
- 210000004443 Dendritic Cells Anatomy 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 2
- 206010020243 Hodgkin's disease Diseases 0.000 claims description 2
- 201000006743 Hodgkin's lymphoma Diseases 0.000 claims description 2
- 102000018358 Immunoglobulins Human genes 0.000 claims description 2
- 108060003951 Immunoglobulins Proteins 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical group C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical group NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 102000005632 Single-Chain Antibodies Human genes 0.000 claims description 2
- 108010070144 Single-Chain Antibodies Proteins 0.000 claims description 2
- 230000001154 acute Effects 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- 201000008325 diseases of cellular proliferation Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 201000003444 follicular lymphoma Diseases 0.000 claims description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 2
- 201000006439 lymphocytic leukemia Diseases 0.000 claims description 2
- 201000008736 systemic mastocytosis Diseases 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 4
- 206010008943 Chronic leukaemia Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010025310 Other lymphomas Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 102000024070 binding proteins Human genes 0.000 claims 1
- 108091007650 binding proteins Proteins 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 230000001413 cellular Effects 0.000 claims 1
- 206010012818 Diffuse large B-cell lymphoma Diseases 0.000 description 3
- 206010024324 Leukaemias Diseases 0.000 description 2
- 208000004860 Blast Crisis Diseases 0.000 description 1
- 208000003747 Lymphoid Leukemia Diseases 0.000 description 1
- 201000002594 Richter's syndrome Diseases 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2018/123108 WO2020132810A1 (en) | 2018-12-24 | 2018-12-24 | Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof |
| CNPCT/CN2018/123108 | 2018-12-24 | ||
| PCT/CN2019/127433 WO2020135335A1 (en) | 2018-12-24 | 2019-12-23 | Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022515258A JP2022515258A (ja) | 2022-02-17 |
| JPWO2020135335A5 true JPWO2020135335A5 (ru) | 2023-01-04 |
Family
ID=71126451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021536788A Pending JP2022515258A (ja) | 2018-12-24 | 2019-12-23 | Ｃｄ１９及びｃｄ３と結合可能な多重特異性抗原結合タンパク質、ならびにその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220064295A1 (ru) |
| EP (1) | EP3902840A4 (ru) |
| JP (1) | JP2022515258A (ru) |
| CN (1) | CN113906054A (ru) |
| AU (1) | AU2019412331A1 (ru) |
| CA (1) | CA3124712A1 (ru) |
| WO (2) | WO2020132810A1 (ru) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103842383B (zh) | 2011-05-16 | 2017-11-03 | 健能隆医药技术（上海）有限公司 | 多特异性fab融合蛋白及其使用方法 |
| KR20230157315A (ko) | 2021-01-28 | 2023-11-16 | 리제너론 파마슈티칼스 인코포레이티드 | 사이토카인 방출 증후군을 치료하기 위한 조성물 및 방법 |
| WO2023201226A1 (en) | 2022-04-11 | 2023-10-19 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
| WO2024097218A1 (en) * | 2022-11-01 | 2024-05-10 | TeneoTwo, Inc. | Methods of treating non-hodgkin lymphoma |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2342227T3 (en) * | 2008-11-07 | 2016-02-15 | Amgen Res Munich Gmbh | TREATMENT OF ACUTE Lymphoblastic Tissue Leukemia |
| CN103842383B (zh) * | 2011-05-16 | 2017-11-03 | 健能隆医药技术（上海）有限公司 | 多特异性fab融合蛋白及其使用方法 |
| US20150017136A1 (en) * | 2013-07-15 | 2015-01-15 | Cellectis | Methods for engineering allogeneic and highly active t cell for immunotherapy |
| WO2014012085A2 (en) * | 2012-07-13 | 2014-01-16 | Zymeworks Inc. | Bispecific asymmetric heterodimers comprising anti-cd3 constructs |
| EP3913000A1 (en) * | 2015-10-02 | 2021-11-24 | F. Hoffmann-La Roche AG | Bispecific anti-cd19xcd3 t cell activating antigen binding molecules |
| WO2017157305A1 (en) * | 2016-03-15 | 2017-09-21 | Generon (Shanghai) Corporation Ltd. | Multispecific fab fusion proteins and use thereof |
| CN108690138A (zh) * | 2017-04-12 | 2018-10-23 | 鸿运华宁（杭州）生物医药有限公司 | 一种能与人cd19或cd20和人cd3结合的双特异性抗体及其应用 |
| CN107903324B (zh) * | 2017-11-15 | 2021-01-29 | 北京绿竹生物技术股份有限公司 | 一种结合人cd19和cd3的双特异性抗体 |
-
2018
- 2018-12-24 WO PCT/CN2018/123108 patent/WO2020132810A1/en active Application Filing
-
2019
- 2019-12-23 JP JP2021536788A patent/JP2022515258A/ja active Pending
- 2019-12-23 WO PCT/CN2019/127433 patent/WO2020135335A1/en unknown
- 2019-12-23 CN CN201980091645.1A patent/CN113906054A/zh active Pending
- 2019-12-23 EP EP19902305.2A patent/EP3902840A4/en active Pending
- 2019-12-23 US US17/417,480 patent/US20220064295A1/en active Pending
- 2019-12-23 CA CA3124712A patent/CA3124712A1/en active Pending
- 2019-12-23 AU AU2019412331A patent/AU2019412331A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018527887A5 (ru) | ||
| US10066015B2 (en) | CD3 binding domains | |
| JP2022075818A5 (ru) | ||
| JP2020504723A5 (ru) | ||
| Fischer et al. | Bispecific antibodies: molecules that enable novel therapeutic strategies | |
| JP2022046674A (ja) | 新規のｂ７‐ｈ３結合分子、その抗体薬物コンジュゲート、及びその使用方法 | |
| HRP20201144T1 (hr) | Protutijela anti-cd3 i postupci uporabe | |
| JP2018519263A5 (ru) | ||
| RU2018100820A (ru) | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА И АНТИТЕЛА С СОЗРЕВШЕЙ АФФИННОСТЬЮ ПРОТИВ FcRH5 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| JP2022185016A5 (ru) | ||
| JP2019524693A5 (ru) | ||
| JP2018503380A5 (ru) | ||
| CN112969476B (zh) | 多特异性蛋白分子 | |
| JP2017529838A5 (ru) | ||
| JP2017534577A5 (ru) | ||
| JP2018510636A5 (ru) | ||
| RU2017110044A (ru) | Антитела и химерные антигенные рецепторы, специфичные к cd19 | |
| JP2018517431A5 (ru) | ||
| JP2018522541A5 (ru) | ||
| RU2014113304A (ru) | Анти-cd40-антитела, применение и методы | |
| RU2013125459A (ru) | АНТИТЕЛА ПРОТИВ БЕЛКА РЕЦЕПТОРА c-Met | |
| JP7500442B2 (ja) | 癌を処置するための組成物及び方法 | |
| RU2017112884A (ru) | Иммуноконъюгаты, содержащие антитела против her2 и пирролбензодиазепины | |
| JP2020511947A5 (ru) | ||
| JP2010509931A5 (ru) |